Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lonza, a Swiss-based supplier to the pharmaceutical and healthcare industries, is set to expand its early phase manufacturing capacity of small molecules in Nansha, China.
Subscribe to our email newsletter
The facility in Nansha operates two small scale trains supplying clinical material, three large scale API trains for metric tons, and cGMP laboratories to meet gram-scale demands.
The company increased its small scale capacity in 2011 with a new cGMP kilo-lab and an additional small scale train that have provided material to support clinical trials for its customers.
Lonza Chemical Manufacturing Business Unit head Stefan Stoffel said the investment would help in the advancement of their efforts to make Lonza Nansha site as a standard of quality to serve the global customer base for all material needs from gram-scale to metric tons.
"With this expansion, Lonza’s FDA approved Nansha site now offers a fully integrated end-to-end development and manufacturing solution for small molecules," Stoffel added.